David Carmody1, Rochelle N Naylor2, Charles D Bell1, Shivani Berry1, Jazzmyne T Montgomery1, Elizabeth C Tadie1, Jessica L Hwang1, Siri Atma W Greeley3, Louis H Philipson3. 1. Department of Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, USA. 2. Departments of Pediatrics and Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, 60637, USA. rnaylor@peds.bsd.uchicago.edu. 3. Departments of Pediatrics and Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, IL, 60637, USA.
Abstract
AIMS: GCK-MODY leads to mildly elevated blood glucose typically not requiring therapy. It has been described in all ethnicities, but mainly in Caucasian Europeans. Here we describe our US cohort of GCK-MODY. METHODS: We examined the rates of detection of heterozygous mutations in the GCK gene in individuals referred to the US Monogenic Diabetes Registry with a phenotype consistent with GCK-MODY. We also assessed referral patterns, treatment and demography, including ethnicity, of the cohort. RESULTS: Deleterious heterozygous GCK mutations were found in 54.7 % of Registry probands selected for GCK sequencing for this study. Forty-nine percent were previously unnecessarily treated with glucose-lowering agents, causing hypoglycemia and other adverse effects in some of the subjects. The proportion of probands found to have a GCK mutation through research-based testing was similar across each ethnic group. However, together African-American, Latino and Asian subjects represented only 20.5 % of screened probands and 17.2 % of those with GCK-MODY, despite higher overall diabetes prevalence in these groups. CONCLUSIONS: Our data show that a high detection rate of GCK-MODY is possible based on clinical phenotype and that prior to genetic diagnosis, a large percentage are inappropriately treated with glucose-lowering therapies. We also find low minority representation in our Registry, which may be due to disparities in diagnostic diabetes genetic testing and is an area needing further investigation.
AIMS: GCK-MODY leads to mildly elevated blood glucose typically not requiring therapy. It has been described in all ethnicities, but mainly in Caucasian Europeans. Here we describe our US cohort of GCK-MODY. METHODS: We examined the rates of detection of heterozygous mutations in the GCK gene in individuals referred to the US Monogenic Diabetes Registry with a phenotype consistent with GCK-MODY. We also assessed referral patterns, treatment and demography, including ethnicity, of the cohort. RESULTS: Deleterious heterozygous GCK mutations were found in 54.7 % of Registry probands selected for GCK sequencing for this study. Forty-nine percent were previously unnecessarily treated with glucose-lowering agents, causing hypoglycemia and other adverse effects in some of the subjects. The proportion of probands found to have a GCK mutation through research-based testing was similar across each ethnic group. However, together African-American, Latino and Asian subjects represented only 20.5 % of screened probands and 17.2 % of those with GCK-MODY, despite higher overall diabetes prevalence in these groups. CONCLUSIONS: Our data show that a high detection rate of GCK-MODY is possible based on clinical phenotype and that prior to genetic diagnosis, a large percentage are inappropriately treated with glucose-lowering therapies. We also find low minority representation in our Registry, which may be due to disparities in diagnostic diabetes genetic testing and is an area needing further investigation.
Authors: Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson Journal: J Diabetes Sci Technol Date: 2011-07-01
Authors: Maria Negahdar; Ingvild Aukrust; Janne Molnes; Marie H Solheim; Bente B Johansson; Jørn V Sagen; Knut Dahl-Jørgensen; Rohit N Kulkarni; Oddmund Søvik; Torgeir Flatmark; Pål R Njølstad; Lise Bjørkhaug Journal: Mol Cell Endocrinol Date: 2013-08-31 Impact factor: 4.102
Authors: David Carmody; Charles D Bell; Jessica L Hwang; Jazzmyne T Dickens; Daniela I Sima; Dania L Felipe; Carrie A Zimmer; Ajuah O Davis; Kateryna Kotlyarevska; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: E A Davis; A Cuesta-Muñoz; M Raoul; C Buettger; I Sweet; M Moates; M A Magnuson; F M Matschinsky Journal: Diabetologia Date: 1999-10 Impact factor: 10.122
Authors: Itziar Estalella; Itxaso Rica; Guiomar Perez de Nanclares; Jose Ramon Bilbao; Jose Antonio Vazquez; Jose Ignacio San Pedro; Maria Angeles Busturia; Luis Castaño Journal: Clin Endocrinol (Oxf) Date: 2007-06-15 Impact factor: 3.478
Authors: Ali J Chakera; Gill Spyer; Nicola Vincent; Sian Ellard; Andrew T Hattersley; Fidelma P Dunne Journal: Diabetes Care Date: 2014-02-18 Impact factor: 19.112
Authors: G Alkorta-Aranburu; D Carmody; Y W Cheng; V Nelakuditi; L Ma; Jazzmyne T Dickens; S Das; S A W Greeley; D Del Gaudio Journal: Mol Genet Metab Date: 2014-09-28 Impact factor: 4.797
Authors: S Ellard; K Thomas; E L Edghill; M Owens; L Ambye; J Cropper; J Little; M Strachan; A Stride; B Ersoy; H Eiberg; O Pedersen; M H Shepherd; T Hansen; L W Harries; A T Hattersley Journal: Diabetologia Date: 2007-09-08 Impact factor: 10.122
Authors: Laura T Dickens; Lisa R Letourneau; May Sanyoura; Siri Atma W Greeley; Louis H Philipson; Rochelle N Naylor Journal: Acta Diabetol Date: 2018-12-11 Impact factor: 4.280
Authors: Amanda J Berberich; Céline Huot; Henian Cao; Adam D McIntyre; John F Robinson; Jian Wang; Robert A Hegele Journal: J Clin Endocrinol Metab Date: 2019-08-01 Impact factor: 5.958
Authors: May Sanyoura; Lisa Letourneau; Amy E Knight Johnson; Daniela Del Gaudio; Siri Atma W Greeley; Louis H Philipson; Rochelle N Naylor Journal: Diabetes Res Clin Pract Date: 2019-05-04 Impact factor: 5.602